Breaking News

Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

Adds ‘off the shelf’ PK profiling capabilities to its portfolio.

Author Image

By: Charlie Sternberg

Associate Editor

Genesis Biotechnology Group (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development (GD3) have acquired the Berkeley-based CRO Integrated Analytical Solutions (IAS).   Founded in 2004 and located in the San Francisco bay area, IAS is a GxP-compliant CRO providing bioanalytical, drug metabolism and analytical chemistry services to clients worldwide.   “This is our second acquisition in the space of two months as we further expand our presence in the S...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters